To support more personalized, value-based healthcare, Oracle announced the introduction of Oracle Health Sciences Translational Research Center, a platform that facilitates the secondary use of healthcare data for both clinical and research organizations.
Oracle Health Sciences Translational Research Center enables pharmaceutical and biotech companies, contract research organizations, as well as academic research organizations to normalize, aggregate and analyze data from numerous internal and external sources to identify new predictive biomarkers, best practices for diagnosis and treatment and more effective and safe therapies for individuals.
A key component of the solution, Oracle Health Sciences Cohort Explorer, helps identify and aggregate patients with similar clinical attributes and puts powerful and easy-to-use analytics directly in the hands of researchers and clinicians, enabling them to be self-sufficient and timely in their analyses, while ensuring a secure foundation that delivers high levels of access control and traceability to support security and regulatory compliance requirements.
To speed time to value and reduce IT complexity and cost, the fully integrated solution is built on Oracle’s proven life sciences and enterprise healthcare analytics solutions. These include Oracle Healthcare Data Warehouse Foundation , a comprehensive and detailed healthcare data model that ensures high quality clinical data is readily accessible to researchers, and Oracle Health Sciences Clinical Development Center , which provides detailed traceability of analysis processes, as well as comprehensive audit capabilities to facilitate regulatory compliance.
The initial release focuses on enabling the aggregation, normalization and analysis of clinical information, such as electronic health record data. It will help health sciences organizations gain insights into how specific patient populations respond to treatments with:
To ensure that the new platform meets the needs of health sciences organizations, Oracle worked closely with numerous development partners, including Merck, Roche, Erasmus University Medical Center, Inova Health System , Moffitt Cancer Center, and Oregon Health & Science University Knight Cancer Institute.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.